Lipigon Pharmaceuticals
0.17
SEK
0 %
LPGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
0%
+0.59%
-36.37%
-39%
-60.51%
-53.5%
-96.95%
-
-97.7%
www.lipigon.se/investerare
Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.
Revenue
16.41M
EBIT %
-75.38 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LPGO
Daily low / high price
0.17 / 0.171
SEK
Market cap
25.25M SEK
Turnover
3.37K SEK
Volume
20K
Financial calendar
Annual report
19.02.2025
Interim report
27.05.2025
Interim report
26.08.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Nordnet Pensionsförsäkring AB | 11.0 % | 11.0 % |
| Försäkringsaktiebolaget Avanza Pension | 4.9 % | 4.9 % |
| Rekonstructa AB | 4.7 % | 4.7 % |
| Ålandsbanken Abp (Finland), svensk filial | 4.0 % | 4.0 % |
| Magbaleo AB | 3.6 % | 3.6 % |
| Handelsbanken Liv Försäkringsaktiebolag | 3.2 % | 3.2 % |
| Fort Knox Förvaring AB | 2.5 % | 2.5 % |
| RJAN Holding AB | 2.1 % | 2.1 % |
| Sip 203, Youplus Assurance | 1.3 % | 1.3 % |
| Loof Andreas | 1.2 % | 1.2 % |
ShowingAll content types
Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools